The high prevalence of ARID1A mutations in ZBTB16‐RARA+AML may extend the applicability of APR‐246 treatment, which also targets TP53‐mutations, and has shown efficacy in TP53 mutated cancers,36, 37 including MDS and AML.38, 39. This evidence concerns the gene ZBTB16 and acute myeloid leukemia.